Imperia Online Quiz October'2018

1. Ezuric is indicated ________

In Acute coronary syndrome

In Stage I hypertension

In Post MI CHF patients

In Nocturnal Hypertension

2. Ezuric is better than ________ due to lesser incidences of adverse effect, better half-life and more no. of patients showing benefits

ARBs and ACE inhibitors

Spironolactone

Beta blockers

None of the above

3. ACCF/AHA 2013 recommends Ezuric (Eplerenone) in patients with ________

NYHA class III-IV and LVEF of

NYHA class II-IV and LVEF of

4. As per EMPHASIS-HF study, Ezuric (Eplerenone) reduces the _______

Risk of death

Risk of hospitalization due to HF

Both a & b

D) Neither a nor b

5. ISDN plus Hydralazine combination is approved by USFDA to manage heart failure.

True

False

6. Diabetes Mellitus patients showed following characteristics in sub analysis of RELY trial:

Stroke or Systemic embolism was more common in DM patients

Increased risk of death and major bleeding

Both a & b

None of the above

7. What are the common risk factors for AF and CAD:

Hypertension, DM, sleep apnea, Obsetity

Inflammation

Smoking

All of the above

8. How is Diabetes Mellitus linked to AF-stroke risk

Diabetes causes AF

Diabetes causes stroke

Diabetes is an important component of CHA2DS2VaSc score

Diabetes is a component of HASBLED score

9. Clot Case Series Issue 9 talks about which of the following topics:

Use of Dabigatran in patient not responding to Warfarin

Use of Dabigatran as preferred NOAC for SPAF

Use of Dabigatran in patient with AF in coronary artery disease

None of the above

10. The study done to evaluate effectiveness of dabigatran in patients undergoing PCi is

REDUAL PCI

RESIDUAL PCI

REMEDIAL PCI

None of the above

11. Number of Effort driven conversions expected per ME for Ezuric and Muzika are ___

5

10

20

25

12. October month input for Ezuric and Muzika is ___

Paper Weight

Chit Pad

Prescription Pad

None of above

13. MUZIKA reduces rate of first hospitalization due to heart failure by ______ % compared to placebo.

33

42

43

35

14. Diabetics who suffer stroke demonstrate ___________ vs the non diabetics:

More severe residual diasability, increased long term mortality

Less severe residual diasability, increased long term comorbidity

Severe Gastrointestinal adverse effects

None of the above

15. Out of 18,113 patients recruited in RELY trial, Diabetes Mellitus was reported in___ patients

4221

4412

4422

4421

16. In EPHESUS survival study, Eplerenone was compared with _______

Placebo

Spironolactone

Both Placebo & Spironolactone

None of above

17. In EMPHASIS-HF, Incidence of Gynecomastia with the use of Eplerenone was seen in _______ % of patients which was less than placebo.

1%

43%

0.7%

35%

18. REDUAL PCI trial involed

2725 adult patients from 40 countries

2775 adult patients from 80 countries

2375 adult patients from 40 countries

19. In REDUAL PCI trial: the two groups received triple therapy consisting of and dual therapy consisting of

Warfarin + Aspirin + Clopidogrel or Ticagrelor, Dabigatran 110/50mg + Clopidogrel or Ticagrelor

Dabigatran 110mg + Aspirin + Clopidogrel or Ticagrelor, Warfarin + Aspirin

Warfarin + Aspirin + Clopidogrel or Ticagrelor, Dabigatran 110/150mg + Aspirin

Warfarin + Aspirin + Clopidogrel or Ticagrelor, Dabigatran 110/50mg + Aspirin + Clopidogrel or Ticagrelor

20. As per REDUAL PCI trial, Dabigatran can be used in AF patients with CAD who have undergone PCI because:

Dabigatran significantly lowers bleeding events and is non inferior to triple therapy

Dabigatran + Clopidogrel significantly lowers bleeding events and is non inferior to triple therapy

Dabigatran + Clopidogrel significantly lowers stroke risk and is non inferior to triple therapy

Dabigatran significantly lowers stroke risk and is non inferior to triple therapy

Imperia Online Quiz October'2018

1. Ezuric is indicated ________

2.

What first name or nickname would you like us to use?

2. Ezuric is better than ________ due to lesser incidences of adverse effect, better half-life and more no. of patients showing benefits

3. ACCF/AHA 2013 recommends Ezuric (Eplerenone) in patients with ________

4. As per EMPHASIS-HF study, Ezuric (Eplerenone) reduces the _______

5. ISDN plus Hydralazine combination is approved by USFDA to manage heart failure.

6. Diabetes Mellitus patients showed following characteristics in sub analysis of RELY trial:

7. What are the common risk factors for AF and CAD:

8. How is Diabetes Mellitus linked to AF-stroke risk

9. Clot Case Series Issue 9 talks about which of the following topics:

10. The study done to evaluate effectiveness of dabigatran in patients undergoing PCi is

11. Number of Effort driven conversions expected per ME for Ezuric and Muzika are ___

12. October month input for Ezuric and Muzika is ___

13. MUZIKA reduces rate of first hospitalization due to heart failure by ______ % compared to placebo.

14. Diabetics who suffer stroke demonstrate ___________ vs the non diabetics:

15. Out of 18,113 patients recruited in RELY trial, Diabetes Mellitus was reported in___ patients

16. In EPHESUS survival study, Eplerenone was compared with _______

17. In EMPHASIS-HF, Incidence of Gynecomastia with the use of Eplerenone was seen in _______ % of patients which was less than placebo.

18. REDUAL PCI trial involed

19. In REDUAL PCI trial: the two groups received triple therapy consisting of ____ and dual therapy consisting of ____

20. As per REDUAL PCI trial, Dabigatran can be used in AF patients with CAD who have undergone PCI because:

19. In REDUAL PCI trial: the two groups received triple therapy consisting of and dual therapy consisting of